Published in Cancer Epidemiol Biomarkers Prev on June 26, 2008
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Prostate cancer genomics: towards a new understanding. Nat Rev Genet (2008) 2.08
Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol (2012) 2.03
Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2009) 1.03
Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol (2010) 0.98
Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS One (2012) 0.87
Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol (2011) 0.85
Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget (2016) 0.75
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Evaluating the yield of medical tests. JAMA (1982) 14.05
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA (2005) 2.85
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed (2004) 2.26
How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol (2006) 2.21
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol (2001) 1.72
Defining aggressive prostate cancer using a 12-gene model. Neoplasia (2006) 1.39
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev (2005) 1.33
The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis. Hum Pathol (1988) 1.23
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol (2003) 1.15
Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol (2003) 1.02
A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol (1989) 0.98
Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer (2005) 0.92
Internet-based Profiler system as integrative framework to support translational research. BMC Bioinformatics (2005) 0.90
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet (2009) 12.96
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med (2008) 12.41
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med (2003) 9.24
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care (2003) 7.40
Mapping human genetic diversity in Asia. Science (2009) 7.40
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr (2002) 6.96
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr (2005) 6.67
Trans fatty acids and cardiovascular disease. N Engl J Med (2006) 6.67
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
A prospective study of sleep duration and mortality risk in women. Sleep (2004) 6.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09